IP20-04: First Results from CORE-008 Cohort CX- Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec with Gemcitabine in Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Friday, May 15, 2026 3:30 PM to 5:30 PM · 1 hr. 59 min. (America/New_York)
146A
Abstract
